2018.Jul.30

Clarification on the news article by Commercial Times

Date of occurrence of the event: Jul 28, 2018 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office Reciprocal shareholding ratios: N/A Name of mass media: Commercial Times Content reported: “OBI…immunohistochemistry (IHC), received the safe to proceed letter from the FDA to be used for OBI-822 Phase […]

HOMEWhat’s NewAnnouncementsClarification on the news article by Commercial Times

Back to List

This article is password protected.

To view the content, please enter your password in the field below

2018.Jul.27

Investigational Device Exemption (IDE) for the development of Adagloxad Simolenin (OBI-822) was approved by the US Food and Drug Administration (FDA) for its use in OBI-822 Phase III Clinical Trial

2018.Aug.15

OBI received notice from patent attorney’s office that product patent for OBI-3424 named "DNA alkylating agents" has been approved by IP Australia